Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Durvalumab after chemoradiotherapy for non-small cell lung cancer: analysis from the patients’ perspective

Posted by on Dec 23, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated the patient-reported outcomes after treatment with durvalumab (Imfinzi) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. This study concluded that durvalumab did not affect the quality of life of these patients. Some background NSCLC is the most common form of lung cancer...

Read More

Adding ramucirumab to erlotinib treatment for patients with advanced non-small cell lung cancer with EGFR mutations

Posted by on Dec 20, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Can bisphosphonates improve treatment outcomes for patients with lung cancer spread to the bones?

Posted by on Nov 3, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated whether zoledronate (Zometa) combined with TKI therapy is more effective than TKI therapy alone for patients with non-small cell lung cancer (NSCLC) spread to the bones. This study concluded that adding zoledronate to TKI therapy improved survival outcomes for these patients. Some background NSCLC is the most common...

Read More

Can adding chemotherapy agents to gefitinib improve outcomes for advanced NSCLC?

Posted by on Oct 28, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated whether adding chemotherapy agents to gefitinib (Iressa) improved outcomes for patients with advanced non-small cell lung cancer (NSCLC). This study found that this combination improved survival but increased side effects for these patients. Some background The gene for epidermal growth factor receptor...

Read More

Evaluating the safety and effectiveness of pembrolizumab in elderly patients with advanced non-small cell lung cancer

Posted by on Oct 20, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of pembrolizumab (Keytruda) in patients of 75 years or older with PD-L1 positive non-small-cell-lung cancer (NSCLC). Authors concluded that pembrolizumab improved overall survival and was safer than chemotherapy in these patients. Some background Lung cancer is one of the most common...

Read More